Pridopidine for the Treatment of Early Huntington’s Disease
Objective: Assess the efficacy of pridopidine 45 mg bid for maintenance of total functional capacity (TFC) and motor function in early HD patients. Background: Pridopidine…The genetic study of hereditary chorea in Kazakhstan
Objective: To analyze the genetic background of hereditary chorea in Kazakhstani population. Background: Hereditary chorea (HC) is a group of inherited movement disorders presenting with…Burden of Huntington’s disease (HD) on loss of employment status and its association with disease stage
Objective: To evaluate the impact of HD on patients’ employment status and understand its association with disease stage. Background: Work disability is an important outcome…Cytokines and Brain Specific Antibodies in Experimental Cellular and Molecular Treatment of Huntington’s Diseases
Objective: Huntington’s Disease (HD) is a severe neurodegenerative disorder main pathogenic factor is CAG repeats in a suffered patients genome. Experimental therapy on the model…TAU pathology contributes to specific patterns of structural brain damage and neuropsychological heterogeneity in Huntington’s disease
Objective: Explore the associations between CSF levels of neurofilament light chain (Nfl), total TAU (tTAU) and phosphorylated TAU (pTAU), structural brain damage and cognitive performance…Detection of Cognitive Changes in Premanifest Huntington’s disease Using the Repeatable Battery for the Assessment of Neuropsychological Status
Objective: The current study is an examination of cognitive changes in premanifest gene carriers for Huntington’s disease (preHD), individuals with manifest Huntington’s disease (HD), and…Motor and non-motor symptoms in Huntington’s disease patients in the Tomsk region, Russia
Objective: The aim is to evaluate features of NMS in PwHD of Tomsk region. Background: Patients with Huntington's disease(PwHD) can complain of other non-motor symptoms(NMS)…Healthcare Utilization and Cost Burden at the End-of-Life Among Medicare Beneficiaries with Huntington’s Disease
Objective: To examine healthcare utilization (HCU) and costs occurring at the end of life among deceased Medicare beneficiaries who were diagnosed with Huntington’s disease (HD).…Longitudinal dynamics of mutant huntingtin and neurofilament light in Huntington’s disease: the prospective HD-CSF study
Objective: To present the mutant huntingtin (mHTT) and neurofilament light (NfL) findings from the two-year prospective longitudinal HD-CSF study, in which an 80-participant cohort of…Development of a time-to-event endpoint for use in premanifest Huntington’s disease (HD) clinical trials
Objective: To develop and evaluate a time-to-event endpoint to measure disease progression in individuals with premanifest HD. Background: HD is typically diagnosed between the ages…
- « Previous Page
- 1
- …
- 778
- 779
- 780
- 781
- 782
- …
- 1554
- Next Page »